Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.

Duska LR, Petroni GR, Lothamer H, Faust W Jr, Beumer JH, Christner SM, Mills AM, Fracasso PM, Parsons SJ.

Cancer Chemother Pharmacol. 2018 Dec 8. doi: 10.1007/s00280-018-3749-7. [Epub ahead of print]

PMID:
30535536
2.

Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi.

Tahata S, Singh SV, Lin Y, Hahm ER, Beumer JH, Christner SM, Rao UN, Sander C, Tarhini AA, Tawbi H, Ferris LK, Wilson M, Rose A, Dietz CM, Hughes E, Fahey JW, Leachman SA, Cassidy PB, Butterfield LH, Zarour HM, Kirkwood JM.

Cancer Prev Res (Phila). 2018 Jul;11(7):429-438. doi: 10.1158/1940-6207.CAPR-17-0268. Epub 2018 Apr 24.

PMID:
29691233
3.

A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.

Redner RL, Beumer JH, Kropf P, Agha M, Boyiadzis M, Dorritie K, Farah R, Hou JZ, Im A, Lim SH, Raptis A, Sehgal A, Christner SM, Normolle D, Johnson DE.

Leuk Lymphoma. 2018 Nov;59(11):2595-2601. doi: 10.1080/10428194.2018.1443330. Epub 2018 Apr 4.

PMID:
29616864
4.

A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Jandial DA, Brady WE, Howell SB, Lankes HA, Schilder RJ, Beumer JH, Christner SM, Strychor S, Powell MA, Hagemann AR, Moore KN, Walker JL, DiSilvestro PA, Duska LR, Fracasso PM, Dizon DS.

Gynecol Oncol. 2017 May;145(2):236-242. doi: 10.1016/j.ygyno.2017.03.013. Epub 2017 Mar 22.

5.

Disease Subtype-Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A.

Samanta SK, Sehrawat A, Kim SH, Hahm ER, Shuai Y, Roy R, Pore SK, Singh KB, Christner SM, Beumer JH, Davidson NE, Singh SV.

J Natl Cancer Inst. 2016 Dec 31;109(6). doi: 10.1093/jnci/djw293. Print 2017 Jun.

6.

Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.

Beumer JH, Pillai VC, Parise RA, Christner SM, Kiesel BF, Rudek MA, Venkataramanan R.

Br J Clin Pharmacol. 2015 Nov;80(5):1097-108. doi: 10.1111/bcp.12723. Epub 2015 Sep 19.

7.

In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4-p53 interaction.

Christner SM, Clausen DM, Beumer JH, Parise RA, Guo J, Huang Y, Dömling AS, Eiseman JL.

Cancer Chemother Pharmacol. 2015 Aug;76(2):287-99. doi: 10.1007/s00280-015-2791-y. Epub 2015 Jun 7.

8.

Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).

Lassman AB, Pugh SL, Gilbert MR, Aldape KD, Geinoz S, Beumer JH, Christner SM, Komaki R, DeAngelis LM, Gaur R, Youssef E, Wagner H, Won M, Mehta MP.

Neuro Oncol. 2015 Jul;17(7):992-8. doi: 10.1093/neuonc/nov011. Epub 2015 Mar 10.

9.

An Automated Homogeneous Immunoassay for Quantitating Imatinib Concentrations in Plasma.

Beumer JH, Kozo D, Harney RL, Baldasano CN, Jarrah J, Christner SM, Parise R, Baburina I, Courtney JB, Salamone SJ.

Ther Drug Monit. 2015 Aug;37(4):486-92. doi: 10.1097/FTD.0000000000000178.

10.

Quantitative method for the determination of iso-fludelone (KOS-1803) in human plasma by LC-MS/MS.

Christner SM, Parise RA, Levine ED, Rizvi NA, Gounder MM, Beumer JH.

J Pharm Biomed Anal. 2014 Nov;100:199-204. doi: 10.1016/j.jpba.2014.08.007. Epub 2014 Aug 12.

11.

Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).

Beumer JH, Owzar K, Lewis LD, Jiang C, Holleran JL, Christner SM, Blum W, Devine S, Kolitz JE, Linker C, Vij R, Alyea EP, Larson RA, Ratain MJ, Egorin MJ.

Cancer Chemother Pharmacol. 2014 Nov;74(5):927-38. doi: 10.1007/s00280-014-2571-0. Epub 2014 Aug 28.

12.

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.

Owonikoko TK, Zhang G, Deng X, Rossi MR, Switchenko JM, Doho GH, Chen Z, Kim S, Strychor S, Christner SM, Beumer J, Li C, Yue P, Chen A, Sica GL, Ramalingam SS, Kowalski J, Khuri FR, Sun SY.

Cancer Med. 2014 Dec;3(6):1579-94. doi: 10.1002/cam4.317. Epub 2014 Aug 13.

13.

Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib--a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer.

Pillai VC, Parise RA, Christner SM, Rudek MA, Beumer JH, Venkataramanan R.

J Clin Pharmacol. 2014 Nov;54(11):1272-9. doi: 10.1002/jcph.333. Epub 2014 May 27.

PMID:
24846165
14.

ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.

Lin F, de Gooijer MC, Roig EM, Buil LC, Christner SM, Beumer JH, Würdinger T, Beijnen JH, van Tellingen O.

Clin Cancer Res. 2014 May 15;20(10):2703-13. doi: 10.1158/1078-0432.CCR-14-0084. Epub 2014 Mar 19.

15.

Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers.

Tawbi H, Christner SM, Lin Y, Johnson M, Mowrey ET, Cherrin C, Chu E, Lee JJ, Puhalla S, Stoller R, Appleman LR, Miller BM, Beumer JH.

Cancer Chemother Pharmacol. 2014 Jan;73(1):207-11. doi: 10.1007/s00280-013-2337-0. Epub 2013 Oct 30.

16.

Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers.

Tawbi HA, Tran AL, Christner SM, Lin Y, Johnson M, Mowrey E, Appleman LR, Stoller R, Miller BM, Egorin MJ, Beumer JH.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1143-7. doi: 10.1007/s00280-013-2283-x. Epub 2013 Sep 14.

17.

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.

Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK.

Br J Cancer. 2013 Oct 1;109(7):1725-34. doi: 10.1038/bjc.2013.553. Epub 2013 Sep 10.

18.

Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.

Pillai VC, Venkataramanan R, Parise RA, Christner SM, Gramignoli R, Strom SC, Rudek MA, Beumer JH.

Drug Metab Dispos. 2013 Oct;41(10):1843-51. doi: 10.1124/dmd.113.052100. Epub 2013 Aug 2.

19.

A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.

Twardowski PW, Beumer JH, Chen CS, Kraft AS, Chatta GS, Mitsuhashi M, Ye W, Christner SM, Lilly MB.

Anticancer Drugs. 2013 Aug;24(7):743-53. doi: 10.1097/CAD.0b013e328361feb0.

20.

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer.

Nabhan C, Villines D, Valdez TV, Tolzien K, Lestingi TM, Bitran JD, Christner SM, Egorin MJ, Beumer JH.

Br J Cancer. 2012 Aug 7;107(4):592-7. doi: 10.1038/bjc.2012.312. Epub 2012 Jul 17.

21.

Effect of a proton pump inhibitor on the pharmacokinetics of imatinib.

Egorin MJ, Shah DD, Christner SM, Yerk MA, Komazec KA, Appleman LR, Redner RL, Miller BM, Beumer JH.

Br J Clin Pharmacol. 2009 Sep;68(3):370-4. doi: 10.1111/j.1365-2125.2009.03466.x.

22.

A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum.

Parise RA, Egorin MJ, Christner SM, Shah DD, Zhou W, Beumer JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jul 1;877(20-21):1894-900. doi: 10.1016/j.jchromb.2009.05.034. Epub 2009 May 21.

Supplemental Content

Loading ...
Support Center